Vertex Initiates Phase 3 Registration Program For VX-770, An Oral CFTR Potentiator Targeting The Defective Protein Responsible For Cystic Fibrosis
Originally posted in Cystic Fibrosis News From Medical News Today
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the initiation of a Phase 3 registration program for VX-770, an investigational Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) potentiator that targets the defective CFTR protein that causes cystic fibrosis (CF).
No Comments
RSS feed for comments on this post.
by Raelene
